| Similar Articles |
|---|
 |
The Motley Fool
April 1, 2008
Brian Lawler |
A Little Up Front and a Lot Later for Cell Genesys Small development-stage drugmaker Cell Genesys announces that it has inked a partnership deal for its lead drug with pharmaceutical giant Takeda.   |
BusinessWeek
February 19, 2007
Gene G. Marcial |
Will Healthy Lab Data Revive Ailing Cell Genesys? Cell genesys is in the midst of clinical trials of vaccines for prostate and pancreatic cancer that analysts believe should catch investors' eyes. |
The Motley Fool
April 30, 2010
Brian Orelli |
Pricey Provenge Pumps Up Dendreon Dendreon's prostate cancer drug is approved, but at what cost, and will insurance pay for it? |
The Motley Fool
November 16, 2007
Brian Lawler |
Waiting on a Friend for Dendreon Dendreon looks for a marketing partner for a prostate cancer drug that's in clinical trials. Investors, take note. |
The Motley Fool
February 24, 2004
David Nierengarten |
Cell Genesys Boosted Cell Genesys's shares jump a day late and a dollar higher. |
The Motley Fool
September 28, 2010
Brian Orelli |
It's Up! It's Down! It's Dendreon! The joys of biotech. |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
The Motley Fool
February 7, 2011
Brian Orelli |
Zibotentan Stopped, Long Live Provenge (for Now) Dendreon is looking good although it's not out of the woods yet. |
The Motley Fool
May 2, 2011
Brian Orelli |
Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
The Motley Fool
January 12, 2004
Dave Marino-Nachison |
All Eyes on Dendreon The cancer fighter's shares rocketed today on good news out of Phase III trials. |
The Motley Fool
December 31, 2010
Brian Orelli |
CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine. |
The Motley Fool
June 23, 2009
Brian Orelli |
Wonder Drug! Maybe? Get the facts before jumping on this one. |
The Motley Fool
May 10, 2006
Brian Lawler |
Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note. |
The Motley Fool
November 10, 2006
Brian Lawler |
Dendreon Pending Approval A lot is riding on what the FDA will say about the small pharma's drug for prostate cancer. Investors, take note. |
Pharmaceutical Executive
June 1, 2007 |
Thoughtleader: Stephen Sherwin, Cell Genesys Cell Genesys has been able to raise enough capital to gamble on what it CEO believes could be the future's most promising therapies, including gene activation, immunotherapy, and oncolytic virus therapy. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
September 10, 2010
Brian D. Pacampara |
A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
BusinessWeek
October 6, 2003
Gene G. Marcial |
Dendreon: New Weapons against Tumors What's so hot about Dendreon, which leaped from 3 last year to 9.25 on Sept. 24? The little-known biotech develops immunologically based cancer remedies, and its lead product, Provenge, is aimed at prostate cancer. |
The Motley Fool
September 29, 2010
Brian Orelli |
Better Buy: Spectrum Pharmaceuticals or Dendreon? A battle of the sales-ramping drugmakers. |
The Motley Fool
May 28, 2010
Brian Orelli |
This Drug Doesn't Work. But All Is Not Lost. Novartis cancer drug fails one trial, but there's still hope. |
The Motley Fool
July 22, 2005
Karl Thiel |
Cancer Drug: A Shot at Success Cancer vaccine pioneer Dendreon delivered news yesterday that its investors have been anxiously awaiting: final three-year survival data from a phase 3 study of Provenge, the company's flagship prostate cancer vaccine. |
The Motley Fool
October 7, 2008
Brian Orelli |
Results IMPACT Volatility at Dendreon Dendreon almost hits both a 52-week high and a 52-week low on the day it releases results. |
The Motley Fool
September 1, 2010
Brian Orelli |
Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge. |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
The Motley Fool
March 13, 2008
Brian Lawler |
Dendreon Rolls the Dice The pharmaceutical amends a phase 3 study on its lead prostate cancer drug. |
The Motley Fool
May 10, 2005
Charly Travers |
Dendreon in the Spotlight The small biotech's prostate cancer drug is in phase 3 development. Is this company worth investing in? |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
The Motley Fool
April 18, 2008
Brian Lawler |
More Good News About Cancer Vaccines Pfizer's deal with Avant for an immunotherapy for brain cancer is promising. |
The Motley Fool
November 3, 2011
David Williamson |
Medivation Investors: Why Your Stock Just Jumped 140% Medivation shares pop on trial success for prostate cancer treatment MDV3100. |
The Motley Fool
November 18, 2010
Brian Orelli |
Worry-Free Dendreon? One step closer to national reimbursement from the Centers for Medicare and Medicaid Services to pay for its prostate cancer treatment Provenge. |
The Motley Fool
May 31, 2011
Brian Orelli |
Profit From This Growing Drug Trend Cancer drugs press on. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
The Motley Fool
February 15, 2008
Brian Lawler |
Dendreon's Not-So-New Data Development-stage drugmaker Dendreon releases "new data" on lead cancer drug Provenge; unfortunately, the data wasn't the data that investors are waiting for. |
The Motley Fool
March 2, 2011
Brian Orelli |
When Will Dendreon Make Money? Not for awhile ... it's a biotech thing. |
The Motley Fool
April 5, 2010
Brian Orelli |
1 Month to Go! Is Dendreon a Buy? Only if you understand the risks. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
September 22, 2010
Brian Orelli |
A Dendreon Deal: It's Not What You Think Dendreon gets help manufacturing Provenge, but there's still work ahead. |
Chemistry World
April 17, 2008
Nuala Mora |
World's first therapeutic cancer vaccine approved In move that will be a fillip to cancer vaccine developers, US biotech Antigenics has won Russian approval to market Oncophage to treat kidney cancer. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
March 4, 2010
Brian Orelli |
Best in Class ... For Now Sanofi's new prostate cancer drug is better than nothing. |
The Motley Fool
December 23, 2011
Selena Maranjian |
3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
August 18, 2010
Travers & Greer |
Dendreon's Big Pharma Future Dendreon has had success with its prostate cancer treatment Provenge. What does Provenge's success mean for the future of Dendreon? |
The Motley Fool
January 17, 2007
Brian Lawler |
Dendreon in the Fast Lane The FDA speeds up review of Dendreon's leading drug candidate. Investors, take note. |
BusinessWeek
April 30, 2007
Catherine Arnst |
Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced. |
The Motley Fool
June 1, 2010
Brian Orelli |
Save Your Money, Dendreon As much as doctors would like to prescribe Dendreon's Provenge for their patients, manufacturing limitations will keep demand outpacing supply for awhile. |
The Motley Fool
January 20, 2004
Dave Marino-Nachison |
Dendreon Calls for Cash Investors don't mind a secondary offering when it comes on the coattails of good news. |
The Motley Fool
August 10, 2011
Jim Mueller |
Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here. |
